NIH Seeks Comments to Extend Researcher Loan Forgiveness

2026-06501 — Government-Owned Inventions; Availability for Licensing

The National Institutes of Health is offering a cool new invention—special human antibodies that can fight certain cancers and autoimmune diseases—for companies to license and develop into treatments. This means businesses can jump on this opportunity to create powerful new medicines using government-backed research. Interested parties should act soon and may need to sign agreements to get full details.

2026-06283 — Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration

The National Eye Institute plans to give Perpetual Biosciences, Inc. an exclusive license to use special PEDF peptides to treat eye diseases that cause vision loss. This means the company will have the sole right to develop and sell this promising treatment, potentially helping millions with retinal degeneration. If you want to comment or apply for a license, act fast—submissions close April 16, 2026!

2026-05957 — Center for Scientific Review; Notice of Closed Meetings

The NIH’s Center for Scientific Review is holding several closed virtual meetings in April 2026 to review and decide on important research grant applications. These meetings affect scientists seeking funding in areas like neuroscience, cancer, and liver disease. No public access is allowed to protect private info and trade secrets, and these reviews help decide where millions in research money will go.

2026-05673 — Center for Scientific Review; Notice of Closed Meetings

The Center for Scientific Review is holding several closed virtual meetings on April 17, 2026, to review and evaluate important grant applications in health and science fields. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.

2026-05672 — National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

The National Institute on Deafness and Other Communication Disorders is holding two closed meetings in late April and early May 2026 to review grant applications and evaluate researchers’ qualifications. These meetings affect scientists seeking funding and help ensure top-notch research gets supported. No public access means privacy is protected, and the process keeps the money flowing to the best projects on time.

2026-05527 — Government-Owned Inventions; Availability for Licensing

The National Institutes of Health is offering a cool new gene-editing invention that can fix a rare genetic disease called ROSAH syndrome, which causes vision loss and other problems. Companies can license this technology to develop treatments that might restore vision and improve lives. Interested parties should act soon and be ready to sign a confidentiality agreement to get all the details.

Previous: 2026-05737 — Citric Acid and Certain Citrate Salts From the People's Republic of China: Final Results of Antidumping Duty Administrative Review; 2023-2024

The U.S. Department of Commerce reviewed sales of citric acid and certain citrate salts from China between May 2023 and April 2024 and found that the Chinese companies did not sell these products at unfairly low prices. This means no extra duties will be charged for this period. The decision is official as of March 24, 2026, keeping trade fair and steady for U.S. buyers and sellers.

Next: 2026-05742 — Sunshine Act Meetings

The Neighborhood Reinvestment Corporation is holding a special board meeting on March 30, 2026, via Zoom. Most of the meeting will be open to the public, but the budget discussion will be private. This affects board members and the public interested in the FY26 budget, with no new costs or timing changes announced.